Hennion & Walsh Asset Management Inc. Buys 18,546 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Hennion & Walsh Asset Management Inc. raised its stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 10.4% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 197,401 shares of the company’s stock after acquiring an additional 18,546 shares during the quarter. Hennion & Walsh Asset Management Inc. owned approximately 0.31% of Viridian Therapeutics worth $4,491,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Principal Financial Group Inc. increased its position in shares of Viridian Therapeutics by 9.7% during the 1st quarter. Principal Financial Group Inc. now owns 11,915 shares of the company’s stock worth $209,000 after purchasing an additional 1,058 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Viridian Therapeutics by 4.1% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 28,822 shares of the company’s stock valued at $505,000 after acquiring an additional 1,135 shares during the last quarter. Swiss National Bank raised its stake in shares of Viridian Therapeutics by 23.4% in the first quarter. Swiss National Bank now owns 82,900 shares of the company’s stock valued at $1,452,000 after acquiring an additional 15,700 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Viridian Therapeutics by 7.8% in the 1st quarter. Vanguard Group Inc. now owns 3,234,279 shares of the company’s stock worth $56,632,000 after acquiring an additional 233,331 shares in the last quarter. Finally, Ameritas Investment Partners Inc. grew its position in Viridian Therapeutics by 19.2% during the 1st quarter. Ameritas Investment Partners Inc. now owns 4,961 shares of the company’s stock worth $87,000 after acquiring an additional 799 shares during the last quarter.

Insider Activity at Viridian Therapeutics

In other news, Director Fairmount Funds Management Llc acquired 1,600,000 shares of Viridian Therapeutics stock in a transaction that occurred on Friday, September 13th. The shares were acquired at an average price of $18.75 per share, with a total value of $30,000,000.00. Following the purchase, the director now directly owns 3,445,813 shares of the company’s stock, valued at $64,608,993.75. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Viridian Therapeutics news, CEO Stephen F. Mahoney purchased 21,400 shares of the stock in a transaction on Friday, September 27th. The stock was bought at an average cost of $23.33 per share, for a total transaction of $499,262.00. Following the completion of the acquisition, the chief executive officer now directly owns 21,400 shares of the company’s stock, valued at $499,262. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Fairmount Funds Management Llc purchased 1,600,000 shares of the company’s stock in a transaction dated Friday, September 13th. The shares were acquired at an average cost of $18.75 per share, for a total transaction of $30,000,000.00. Following the transaction, the director now owns 3,445,813 shares of the company’s stock, valued at $64,608,993.75. This trade represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought 1,626,400 shares of company stock worth $30,616,312 in the last ninety days. Company insiders own 0.65% of the company’s stock.

Viridian Therapeutics Stock Performance

VRDN stock opened at $23.39 on Thursday. Viridian Therapeutics, Inc. has a twelve month low of $10.93 and a twelve month high of $25.39. The company has a quick ratio of 15.82, a current ratio of 15.82 and a debt-to-equity ratio of 0.05. The company has a market cap of $1.49 billion, a P/E ratio of -5.20 and a beta of 1.08. The business’s fifty day moving average is $19.90 and its 200-day moving average is $16.02.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings data on Thursday, August 8th. The company reported ($1.02) EPS for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.15). Viridian Therapeutics had a negative net margin of 79,185.77% and a negative return on equity of 83.18%. The company had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.09 million. Equities research analysts forecast that Viridian Therapeutics, Inc. will post -3.94 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on VRDN. Wedbush reissued an “outperform” rating and issued a $42.00 price objective on shares of Viridian Therapeutics in a research note on Monday, July 29th. BTIG Research upped their price target on shares of Viridian Therapeutics from $56.00 to $61.00 and gave the stock a “buy” rating in a research report on Thursday, September 26th. HC Wainwright restated a “buy” rating and issued a $27.00 price objective on shares of Viridian Therapeutics in a research report on Tuesday, September 10th. Needham & Company LLC boosted their target price on shares of Viridian Therapeutics from $30.00 to $38.00 and gave the stock a “buy” rating in a research note on Wednesday, September 11th. Finally, Oppenheimer reissued an “outperform” rating and issued a $28.00 price target (down previously from $31.00) on shares of Viridian Therapeutics in a report on Monday, August 12th. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $35.80.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.